| 20th Dec 2024 7:00 am |
RNS |
Headline results from phase III FIRST trial |
| 16th Dec 2024 7:11 am |
RNS |
Jemperli receives US FDA breakthrough designation |
| 16th Dec 2024 7:05 am |
RNS |
EMA grants PRIME Designation for GSK’227 |
| 16th Dec 2024 7:00 am |
RNS |
Jemperli receives positive CHMP opinion |
| 12th Dec 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 9th Dec 2024 6:29 pm |
RNS |
Overall survival data presented for Blenrep |
| 9th Dec 2024 7:05 am |
RNS |
Blenrep combination China filing acceptance |
| 9th Dec 2024 7:00 am |
RNS |
Nucala COPD submission accepted by US FDA |
| 5th Dec 2024 7:00 am |
RNS |
Zhifei China collaboration revised and extended |
| 2nd Dec 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 2nd Dec 2024 3:00 pm |
RNS |
Total Voting Rights |
| 27th Nov 2024 7:00 am |
RNS |
GSK liquid meningitis vaccine authorised in EU |
| 25th Nov 2024 7:00 am |
RNS |
Blenrep combinations accepted for US FDA review |
| 22nd Nov 2024 7:00 am |
RNS |
Japan approves first RSV vaccine for adults 50-59 |
| 19th Nov 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 19th Nov 2024 7:00 am |
RNS |
GLISTEN Trial of Linerixibat Meets Endpoint |
| 14th Nov 2024 7:00 am |
RNS |
GSK announces overall survival results for Blenrep |
| 13th Nov 2024 3:00 pm |
RNS |
Block listing Interim Review |
| 12th Nov 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 11th Nov 2024 3:01 pm |
RNS |
GSK publishes provisional 2025 dividend dates |
| 1st Nov 2024 3:00 pm |
RNS |
Total Voting Rights |
| 30th Oct 2024 2:29 pm |
RNS |
Director/PDMR Shareholding |
| 30th Oct 2024 7:00 am |
RNS |
3rd Quarter Results |
| 24th Oct 2024 7:00 am |
RNS |
New positive Arexvy data in younger adults at risk |
| 17th Oct 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 16th Oct 2024 4:09 pm |
RNS |
Director/PDMR Shareholding |
| 16th Oct 2024 7:00 am |
RNS |
FDA accepts new drug application for gepotidacin |
| 14th Oct 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 14th Oct 2024 7:00 am |
RNS |
Positive results of ANCHOR trials of depemokimab |
| 11th Oct 2024 3:33 pm |
RNS |
Director/PDMR Shareholding |
| 10th Oct 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 9th Oct 2024 5:48 pm |
RNS |
Zantac (ranitidine) litigation settlements |
| 8th Oct 2024 11:45 am |
RNS |
Positive efficacy data of Arexvy over 3 seasons |
| 1st Oct 2024 3:00 pm |
RNS |
Total Voting Rights |
| 24th Sep 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 24th Sep 2024 7:00 am |
RNS |
Positive EU opinion for GSK liquid Menveo vaccine |
| 18th Sep 2024 1:20 pm |
RNS |
Statement: Zantac (ranitidine) litigation |
| 17th Sep 2024 7:00 am |
RNS |
Japan Filing Acceptance: Blenrep Multiple Myeloma |
| 13th Sep 2024 7:00 am |
RNS |
China Breakthrough Therapy Designation for Blenrep |
| 12th Sep 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
